NU-DUL-1细胞

NU-DUL-1细胞NU-DUL-1细胞NU-DUL-1;人弥漫性B细胞淋巴瘤细胞

Cell line name    NU-DUL-1
Synonyms    NUDUL-1; NUDUL1
Accession    CVCL_1877
Resource Identification Initiative    To cite this cell line use: NU-DUL-1 (RRID:CVCL_1877)
Comments    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: ~30-36 hours (DSMZ=ACC-579).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Virome analysis using RNAseq.
Derived from site: In situ; Cerebrospinal fluid; UBERON=UBERON_0001359.
Sequence variations    
Mutation; HGNC; 6407; KRAS; Simple; p.Asp119Asn (c.355G>A); ClinVar=VCV000040460; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
Mutation; HGNC; 11998; TP53; Simple; p.Val143Met (c.427G>A); ClinVar=VCV000142657; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP=1330982; DepMap=ACH-000287).
HLA typing    Source: PubMed=25960936
Class I
HLA-A    A*24:02,02:01
HLA-B    B*49:01,49:01
HLA-C    C*07:01,07:01
Class II
HLA-DQ    DQA1*05:01,05:01
DQB1*03:01,03:01
HLA-DR    DRB1*12:01,03:02

Source: PubMed=26589293
Class I
HLA-A    A*24:02,24:02
HLA-B    B*49:01,49:01
HLA-C    C*07:01,07:01
Genome ancestry    Source: PubMed=30894373

Origin    % genome
African    0
Native American    0
East Asian, North    1.39
East Asian, South    0.48
South Asian    1.36
European, North    63.99
European, South    32.78
Disease    Diffuse large B-cell lymphoma activated B-cell type (NCIt: C36081)
Diffuse large B-cell lymphoma (ORDO: Orphanet_544)
Species of origin    Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell    Male
Age at sampling    43Y
Category    Cancer cell line
STR profile    Source(s): ATCC=CRL-2969; Cosmic-CLP=1330982; DSMZ=ACC-579

Markers:
Amelogenin    X
CSF1PO    11,12
D2S1338    24,25
D3S1358    14,16
D5S818    12,14
D7S820    11,13
D8S1179    13
D13S317    8,13
D16S539    11,13
D18S51    13,14
D19S433    14,15
D21S11    28,32.2
FGA    22
Penta D    9,13
Penta E    10,13
TH01    9,9.3
TPOX    8
vWA    16,17

Run an STR similarity search on this cell line
Publications    
PubMed=2581902; DOI=10.1002/ijc.2910350509
Epstein A.L., Variakojis D., Berger C.S., Kaiser-McCaw Hecht B.
Use of novel chemical supplements in the establishment of three human malignant lymphoma cell lines (NU-DHL-1, NU-DUL-1, and NU-AMB-1) with chromosome 14 translocations.
Int. J. Cancer 35:619-627(1985)

PubMed=19278952; DOI=10.1182/blood-2009-01-202028; PMCID=PMC3401058
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23699601; DOI=10.1182/blood-2013-02-483727; PMCID=PMC3744992
Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.W., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S.P., Jones S.J.M., Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D., Marra M.A.
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Blood 122:1256-1265(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., MiroT., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)